Career history of Todd C. Zankel
Former positions of Todd C. Zankel
| Companies | Position | Start | End |
|---|---|---|---|
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Chief Tech/Sci/R&D Officer | 2009-09-30 | 2009-09-30 |
| Founder | 2009-09-30 | 2009-09-30 | |
| BIOMARIN PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 1996-12-31 | 2004-12-31 |
| RAPTOR PHARMACEUTICAL CORP | Founder | 2009-09-28 | - |
| Raptor Pharmaceutical, Inc. | Chief Tech/Sci/R&D Officer | 2005-12-31 | - |
| Founder | 2010-11-23 | - |
Training of Todd C. Zankel
| The Reed Institute | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Statistics
International
| United States | 7 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 3 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Private companies | 3 |
|---|---|
| Raptor Pharmaceutical, Inc. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
- Stock Market
- Insiders
- Todd C. Zankel
- Experience
